JP2001513764A - 5−ht2a拮抗剤としてのオキサゾリジン類 - Google Patents
5−ht2a拮抗剤としてのオキサゾリジン類Info
- Publication number
- JP2001513764A JP2001513764A JP53722398A JP53722398A JP2001513764A JP 2001513764 A JP2001513764 A JP 2001513764A JP 53722398 A JP53722398 A JP 53722398A JP 53722398 A JP53722398 A JP 53722398A JP 2001513764 A JP2001513764 A JP 2001513764A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- indolyl
- piperidinylmethyl
- oxazolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式I [式中、R1は、H、CN、Hal又はOAであり、 R2、R3は、それぞれ互いに独立してH、CN、Hal又はOAであり、 R2及びR3は、一緒になってメチレンジオキシであってもよく、 Aは、H、CF3、又は1個から6個のC原子をもつアルキル、そしてHalは 、F、Cl、Br、Iである]の化合物、及びそれらの塩。 2. 請求項1に記載の式Iの化合物のエナンチオマー。 3. a)(5S)−(−)3−(4−クロロフェニル)−5−[4−(3−インド リル)−1−ピペリジニルメチル]オキサゾリジン−2−オン; b)3−(4−シアノフェニル)−5−[4−(5−シアノ−3−インドリル )−1−ピペリジニルメチル]オキサゾリジン−2−オン; c)(5S)−(−)−3−(4−シアノフェニル)−5−[4−(6−フル オロ−3−インドリル)−1−ピペリジニルメチル]オキサゾリジン−2 −オン; d)(5R)−(+)−3−(4−シアノフェニル)−5−[4−(5−フル オロ−3−インドリル)−1−ピペリジニルメチル]オキサゾリジン−2 −オン; e)(5R)−(+)−3−(4−シアノフェニル)−5−[4−(6−フル オロ−3−インドリル)−1−ピペリジニルメチル]オキサゾリジン−2 −オン; f)3−フェニル−5−[4−(5−シアノ−3−インドリル)−1−ピペリ ジニルメチル]オキサゾリジン−2−オン; g)3−フェニル-5−[4−(6−フルオロ−3−インドリル)−1−ピぺ リジニルメチル]オキサゾリジン−2−オン; である、請求項1又は2に記載の式Iの化合物及びそれらの塩。 4. 請求項1に記載の式Iの化合物の製造方法であって、 a) 式II [式中、R1は、請求項1において述べられる意味を有し、LはCl、Br、I 又は遊離のOH基又は反応機能的に修飾されたOH基である]の化合物を、式I II [式中、R2及びR3は、請求項1に与えられる意味を有する]の化合物と反応さ せるか、又は b) 式IV [式中、R1、R2及びR3は、請求項1に与えられる意味を有する]の化合物を 、式V [式中、L及びL'は、それぞれ互いに独立してCl、Br、I又は遊離のOH 基又は反応機能的に修飾されたOH基である]の化合物と反応させるか、又は c) 式VI [式中、R1、R2及びR3は、請求項1に述べられた意味を有する]の化合物を 水素添加するか、 及び/又は式Iの塩基性化合物を酸と処理してその塩に変換することを特徴とす る、前記方法。 5. 医薬組成物の製造方法であって、請求項1に記載の式Iの化合物及び/又 はその生理学的に許容される塩の1つ又はそのエナンチオマーの1つが、少なく とも1つの固体、液体又は半固体の賦形剤又は補助剤と一緒に、そして適宜1又 は2以上の活性成分と組み合わせて、適当な投薬剤形に変換することを特徴とす る、前記方法。 6. 請求項1又は2のいずれかに記載の少なくとも1つの化合物、及び/又は その生理学的に許容できる塩の1つを含むことを特徴とする、医薬組成物。 7. 卒中及び脳虚血の後遺症をコントロールしたり、強迫性障害(OCD)、 不安状態、パニック発作、うつ病、精神病、精神分裂病及びパーキンソン氏病の 治療に対する、請求項1に記載の式Iの化合物及びそれらの生理学的に許容でき る塩。 8. 5−HT再取り込み阻害作用をもつ5−HT2A拮抗剤としての、請求項1 に記載の式Iの医薬及びその生理学的に許容できる塩。 9. 請求項1に記載の式Iの化合物及び/又はそれらの生理学的に許容できる 塩の、医薬を製造するための使用。 10. 請求項1に記載の式Iの化合物及び/又はそれらの生理学的に許容でき る塩 の、卒中及び脳虚血の後遺症をコントロールし、強迫性障害(OCD)、不安状 態、パニック発作、うつ病、精神病、精神分裂病及びパーキンソン氏病の治療す るための使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19707628A DE19707628A1 (de) | 1997-02-26 | 1997-02-26 | Oxazolidinone |
DE19707628.9 | 1997-02-26 | ||
PCT/EP1998/000637 WO1998038189A1 (de) | 1997-02-26 | 1998-02-06 | Oxazolidinone als 5-ht2a-antagonisten |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009149274A Division JP2009256363A (ja) | 1997-02-26 | 2009-06-24 | 5−ht2a拮抗剤としてのオキサゾリジン類 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001513764A true JP2001513764A (ja) | 2001-09-04 |
JP2001513764A5 JP2001513764A5 (ja) | 2005-10-06 |
JP4402175B2 JP4402175B2 (ja) | 2010-01-20 |
Family
ID=7821498
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53722398A Expired - Fee Related JP4402175B2 (ja) | 1997-02-26 | 1998-02-06 | 5−ht2a拮抗剤としてのオキサゾリジン類 |
JP2009149274A Pending JP2009256363A (ja) | 1997-02-26 | 2009-06-24 | 5−ht2a拮抗剤としてのオキサゾリジン類 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009149274A Pending JP2009256363A (ja) | 1997-02-26 | 2009-06-24 | 5−ht2a拮抗剤としてのオキサゾリジン類 |
Country Status (25)
Country | Link |
---|---|
US (1) | US6462056B1 (ja) |
EP (1) | EP0964863B1 (ja) |
JP (2) | JP4402175B2 (ja) |
KR (1) | KR20000075697A (ja) |
CN (1) | CN1177847C (ja) |
AR (1) | AR010899A1 (ja) |
AT (1) | ATE240954T1 (ja) |
AU (1) | AU739251B2 (ja) |
BR (1) | BR9807765A (ja) |
CA (1) | CA2281918C (ja) |
CZ (1) | CZ299199A3 (ja) |
DE (2) | DE19707628A1 (ja) |
DK (1) | DK0964863T3 (ja) |
ES (1) | ES2197466T3 (ja) |
HU (1) | HUP0001093A3 (ja) |
ID (1) | ID22838A (ja) |
NO (1) | NO313415B1 (ja) |
PL (1) | PL335100A1 (ja) |
PT (1) | PT964863E (ja) |
RU (1) | RU2196140C2 (ja) |
SK (1) | SK112799A3 (ja) |
TW (1) | TW531538B (ja) |
UA (1) | UA58542C2 (ja) |
WO (1) | WO1998038189A1 (ja) |
ZA (1) | ZA981579B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2787328A1 (fr) * | 1998-12-22 | 2000-06-23 | Sanofi Sa | Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures |
EP1146871A4 (en) * | 1999-01-28 | 2002-04-17 | Bristol Myers Squibb Co | HETEROCYCLIC ANTIDEPRESSANT COMPOUNDS |
ES2165274B1 (es) | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
CA2341542A1 (en) * | 1999-06-24 | 2000-12-28 | Toray Industries, Inc. | .alpha.1b-adrenergic receptor antagonists |
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
ES2172436B1 (es) | 2000-10-31 | 2004-01-16 | Almirall Prodesfarma Sa | Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
DE60212959T2 (de) * | 2001-04-07 | 2007-02-15 | Astrazeneca Ab | Eine sulfonimid-gruppe enthaltende oxazolidinone als antibiotika |
JPWO2004069828A1 (ja) * | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
EP1691811B1 (en) | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
CL2008001002A1 (es) * | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
PL2245028T3 (pl) * | 2007-12-18 | 2012-07-31 | Actelion Pharmaceuticals Ltd | Pochodne 5-aminocyklilometyloksazolidyn-2-onu |
ES2628091T3 (es) * | 2008-10-10 | 2017-08-01 | Idorsia Pharmaceuticals Ltd | Antibióticos de oxazolidinilo |
WO2014046544A1 (en) | 2012-09-21 | 2014-03-27 | Aapa B.V. | Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3723797A1 (de) * | 1987-07-18 | 1989-01-26 | Merck Patent Gmbh | Oxazolidinone |
DE4005371A1 (de) * | 1990-02-21 | 1991-08-22 | Merck Patent Gmbh | Oxazolidinone |
DE4017211A1 (de) * | 1990-05-29 | 1991-12-05 | Merck Patent Gmbh | Oxazolidinone |
DK152090D0 (da) | 1990-06-22 | 1990-06-22 | Lundbaek A S H | Piperidylsubstituerede indolderivater |
DK158590D0 (da) * | 1990-07-02 | 1990-07-02 | Lundbeck & Co As H | Indolderivater |
DE4324393A1 (de) * | 1993-07-21 | 1995-01-26 | Merck Patent Gmbh | 4-Aryloxy- und 4-Arylthiopiperidinderivate |
DE4414113A1 (de) * | 1994-04-22 | 1995-10-26 | Merck Patent Gmbh | 3-Indolylpiperidine |
ZA954689B (en) * | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
DE19500689A1 (de) * | 1995-01-12 | 1996-07-18 | Merck Patent Gmbh | Indolpiperidin-Derivate |
-
1997
- 1997-02-26 DE DE19707628A patent/DE19707628A1/de not_active Withdrawn
-
1998
- 1998-02-06 AU AU63949/98A patent/AU739251B2/en not_active Ceased
- 1998-02-06 AT AT98909397T patent/ATE240954T1/de not_active IP Right Cessation
- 1998-02-06 PL PL98335100A patent/PL335100A1/xx unknown
- 1998-02-06 BR BR9807765-1A patent/BR9807765A/pt not_active IP Right Cessation
- 1998-02-06 PT PT98909397T patent/PT964863E/pt unknown
- 1998-02-06 CA CA002281918A patent/CA2281918C/en not_active Expired - Fee Related
- 1998-02-06 US US09/380,202 patent/US6462056B1/en not_active Expired - Fee Related
- 1998-02-06 CN CNB988028344A patent/CN1177847C/zh not_active Expired - Fee Related
- 1998-02-06 WO PCT/EP1998/000637 patent/WO1998038189A1/de not_active Application Discontinuation
- 1998-02-06 ID IDW990813D patent/ID22838A/id unknown
- 1998-02-06 EP EP98909397A patent/EP0964863B1/de not_active Expired - Lifetime
- 1998-02-06 HU HU0001093A patent/HUP0001093A3/hu unknown
- 1998-02-06 CZ CZ992991A patent/CZ299199A3/cs unknown
- 1998-02-06 SK SK1127-99A patent/SK112799A3/sk unknown
- 1998-02-06 DE DE59808461T patent/DE59808461D1/de not_active Expired - Lifetime
- 1998-02-06 KR KR1019997007764A patent/KR20000075697A/ko not_active Application Discontinuation
- 1998-02-06 ES ES98909397T patent/ES2197466T3/es not_active Expired - Lifetime
- 1998-02-06 RU RU99120183/04A patent/RU2196140C2/ru not_active IP Right Cessation
- 1998-02-06 JP JP53722398A patent/JP4402175B2/ja not_active Expired - Fee Related
- 1998-02-06 DK DK98909397T patent/DK0964863T3/da active
- 1998-02-23 TW TW087102539A patent/TW531538B/zh not_active IP Right Cessation
- 1998-02-25 ZA ZA981579A patent/ZA981579B/xx unknown
- 1998-02-26 AR ARP980100858A patent/AR010899A1/es not_active Application Discontinuation
- 1998-06-02 UA UA99095309A patent/UA58542C2/uk unknown
-
1999
- 1999-08-25 NO NO19994106A patent/NO313415B1/no not_active IP Right Cessation
-
2009
- 2009-06-24 JP JP2009149274A patent/JP2009256363A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2281918A1 (en) | 1998-09-03 |
CN1177847C (zh) | 2004-12-01 |
DE59808461D1 (de) | 2003-06-26 |
ID22838A (id) | 1999-12-09 |
NO994106D0 (no) | 1999-08-25 |
KR20000075697A (ko) | 2000-12-26 |
PT964863E (pt) | 2003-10-31 |
ES2197466T3 (es) | 2004-01-01 |
EP0964863A1 (de) | 1999-12-22 |
ZA981579B (en) | 1999-03-17 |
SK112799A3 (en) | 2000-06-12 |
AU739251B2 (en) | 2001-10-04 |
JP4402175B2 (ja) | 2010-01-20 |
TW531538B (en) | 2003-05-11 |
UA58542C2 (uk) | 2003-08-15 |
AR010899A1 (es) | 2000-07-12 |
PL335100A1 (en) | 2000-04-10 |
BR9807765A (pt) | 2000-02-22 |
ATE240954T1 (de) | 2003-06-15 |
WO1998038189A1 (de) | 1998-09-03 |
HUP0001093A3 (en) | 2001-07-30 |
AU6394998A (en) | 1998-09-18 |
CZ299199A3 (cs) | 1999-11-17 |
JP2009256363A (ja) | 2009-11-05 |
DK0964863T3 (da) | 2003-08-04 |
NO994106L (no) | 1999-10-19 |
US6462056B1 (en) | 2002-10-08 |
HUP0001093A2 (hu) | 2001-06-28 |
CN1248973A (zh) | 2000-03-29 |
EP0964863B1 (de) | 2003-05-21 |
DE19707628A1 (de) | 1998-08-27 |
RU2196140C2 (ru) | 2003-01-10 |
NO313415B1 (no) | 2002-09-30 |
CA2281918C (en) | 2007-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009256363A (ja) | 5−ht2a拮抗剤としてのオキサゾリジン類 | |
RU2284323C2 (ru) | Фенилэтенил- или фенилэтенилпроизводные в качестве антагонистов глутаматного рецептора | |
JP4740115B2 (ja) | 置換ピラゾール | |
JPH10508824A (ja) | タキキニンアンタゴニストとしてのベンゾフラン誘導体 | |
JP7094989B2 (ja) | シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト | |
RU2382766C2 (ru) | Производные арилсульфонилстильбена для лечения бессонницы и связанных с ней расстройств | |
JP3834098B2 (ja) | ベンゾニトリル類およびベンゾフルオリド類 | |
JP2008519083A (ja) | アミノキナゾリン化合物 | |
JP2005507872A (ja) | 3−置換オキシインドールβ3アゴニスト | |
TW201036960A (en) | Benzofuran derivatives | |
JP2011153144A (ja) | 置換ピラゾール化合物 | |
JP4740116B2 (ja) | 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト | |
SE465928B (sv) | 1,2,4-triazolonfoereningar med antidepressiv aktivitet, foerfarande foer framstaellning av dessa och en farmaceutisk komposition | |
AU2021410119A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
JP4833832B2 (ja) | ピラゾール化合物 | |
JPH11199573A (ja) | 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体 | |
JPH08165276A (ja) | 2−アルキルアミノ−1−フェニルエタノール誘導体 | |
CZ2002499A3 (cs) | Derivát piperidinalkoholu, způsob jeho přípravy, jeho pouľití a farmaceutický prostředek, který ho obsahuje | |
JP2002535329A (ja) | 置換1−(4−ピペリジル)−3−(アリール)イソチオウレア類、その調製およびその治療用途 | |
KR20240046553A (ko) | Sting 길항제로서의 소분자 우레아 유도체 | |
WO2013168759A1 (ja) | 芳香環化合物 | |
MXPA99007866A (en) | Oxazolidines as 5-ht2a-antagonists | |
JP2586552B2 (ja) | ピペラジン化合物 | |
JPWO2002042297A1 (ja) | ピペリジン化合物およびその医薬用途 | |
JPH0641079A (ja) | ピリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081219 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090624 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090929 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091029 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |